Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
07/2012
07/17/2012CA2624544C Vero cell line adapted to grow in suspension
07/17/2012CA2579882C Edible vaccine
07/17/2012CA2488366C Biofunctional cpg or oligo-/polynucleotide and toxin or enterotoxin containing composition
07/17/2012CA2487968C A novel drug dosing regimen
07/17/2012CA2478478C Coupling hydroxyalkyl starch via a terminal aldehyde group or a functional group derived therefrom, to a protein
07/17/2012CA2462455C Development of a preventive vaccine for filovirus infection in primates
07/17/2012CA2434000C Adjuvant viral particle
07/17/2012CA2391392C Methods for screening candidate drugs that disrupt mif and jab1 interaction, mif and jab1 complex, antibodies and uses thereof
07/17/2012CA2355976C Vascular endothelial cell growth factor antagonists and uses thereof
07/17/2012CA2266325C A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
07/12/2012WO2012094623A2 Anti-il-12/il-23 antibodies and uses thereof
07/12/2012WO2012094587A1 Plasma kallikrein binding proteins
07/12/2012WO2012094386A1 Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
07/12/2012WO2012094300A2 Methods of treating age-related macular degeneration
07/12/2012WO2012094252A1 Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
07/12/2012WO2012094163A1 Methods and kits for topical application, removal, and inactivation of therapeutic or cosmetic toxin compositions
07/12/2012WO2012093733A1 Method for producing anti-signal peptide antibody
07/12/2012WO2012093704A1 Method for improving physical properties of antibody
07/12/2012WO2012093681A1 Method for selecting patient to be given drug for treating septicemia
07/12/2012WO2012093406A2 A combination heptavalent vaccine
07/12/2012WO2012093137A1 Liposome formulation suitable for treating or preventing tuberculosis
07/12/2012WO2012093068A1 A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
07/12/2012WO2012092934A1 Monomeric and multimeric immunogenic peptides
07/12/2012WO2012092850A1 Anti-alcoholism drug and preparation method therefor
07/12/2012WO2012092665A1 Method for facilitating tissue transplantation
07/12/2012WO2012092664A1 Monoclonal anti-anti-mhc antibodies and uses thereof
07/12/2012WO2012092663A1 Monoclonal anti-anti-anti-mhc antibodies and uses thereof
07/12/2012WO2012071216A3 Antibodies for tumor gangliosides
07/12/2012WO2012065055A3 Fusion proteins for hiv therapy
07/12/2012WO2012044756A3 Basophil activation based allergy diagnostic test
07/12/2012WO2012037551A3 Primary cell-derived biologic and wt1 synthetic long peptide vaccine
07/12/2012WO2012031280A3 Identification and enrichment of cell subpopulations
07/12/2012US20120179143 Process for in vivo treatment of specific biological targets in bodily fluids
07/12/2012US20120178912 RECEPTOR ACTIVATOR OF NF-kappaB
07/12/2012US20120178629 Apparatus and methods for preparing an emulsion
07/12/2012US20120178163 Novel tumor necrosis factor receptor homologs and nucleic acids encoding the same
07/12/2012US20120178157 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
07/12/2012US20120178107 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
07/12/2012US20120178102 Characterization of granulocytic ehrlichia and methods of use
07/12/2012US20120177740 Drug delivery formulation for controlling of initial burst and manufacturing method thereof
07/12/2012US20120177724 Lipid vesicle compositions and methods of use
07/12/2012US20120177721 Formulation
07/12/2012US20120177704 Crystalline anti-human il-12 antibodies
07/12/2012US20120177701 Compositions comprising immunostimulatory nucleic acids and related methods
07/12/2012US20120177695 Bioerodible Silicon-Based Devices for Delivery of Therapeutic Agents
07/12/2012US20120177689 Generation of novel bone forming cells (monoosteophils) from ll-37 treated monocytes
07/12/2012US20120177688 Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology
07/12/2012US20120177687 Gene expressing a bifidobacterium surface-presented fusion protein
07/12/2012US20120177686 Vaccine for the prevention of acute lymphoblastic leukemia
07/12/2012US20120177685 Peptide vaccines against group a streptococci
07/12/2012US20120177684 Papillomavirus vaccine compositions
07/12/2012US20120177683 Methods for preparing vesicles and formulations produced therefrom
07/12/2012US20120177681 Formulation of immunopotentiators
07/12/2012US20120177680 Polypeptides and methods for the specific detection of antibodies in patients with a borrelia infection
07/12/2012US20120177679 Matrix metalloproteinase 11 vaccine
07/12/2012US20120177678 Compositions and methods for treatment of cervical dysplasia
07/12/2012US20120177677 Antigen specific multi epitope-based anti-infective vaccines
07/12/2012US20120177676 Alphabodies for hiv entry inhibition
07/12/2012US20120177675 Chimaeric Protein
07/12/2012US20120177673 Immunity-inducing agent
07/12/2012US20120177672 Therapeutic peptides, polypeptides and nucleic acid sequences
07/12/2012US20120177671 Hla-g alpha 1 multimers and pharmaceutical uses thereof
07/12/2012US20120177670 Somatic Stem Cells
07/12/2012US20120177669 Phosphopeptides as melanoma vaccines
07/12/2012US20120177668 Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor
07/12/2012US20120177667 Metal Abstraction Peptide (MAP) Tag and Associated Methods
07/12/2012US20120177666 Anti-tgf-beta receptor ii antibodies
07/12/2012US20120177665 Method of diagnosing and treating interstitial cystitis
07/12/2012US20120177664 Antibodies That Specifically Bind to A Beta Oligomers and Use Thereof
07/12/2012US20120177663 Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins
07/12/2012US20120177662 Alpha-4-beta-7 heterodimer specific antagonist antibody
07/12/2012US20120177661 Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor
07/12/2012US20120177660 Biomarkers and therapeutic targets for type 1 diabetes
07/12/2012US20120177659 Methods and compositions for treating and diagnosing diseases
07/12/2012US20120177658 Methods of treatment using an anti il b50 antibody
07/12/2012US20120177657 Fusion proteins comprising cd4 minimal modules and methods of use thereof
07/12/2012US20120177656 Compounds and Methods for the Modulation of Sulfilimine Bond Formation
07/12/2012US20120177655 Anti-human il-21 monoclonal antibodies
07/12/2012US20120177654 Method of treatment and agents useful for same
07/12/2012US20120177653 Antibodies that bind both il-17a and il-17f and methods of using the same
07/12/2012US20120177652 Bispecific binding agents for modulating biological activity
07/12/2012US20120177651 Antigen-binding proteins
07/12/2012US20120177650 Therapy for enteric infections
07/12/2012US20120177649 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
07/12/2012US20120177648 Anti-tlr4 antibodies and methods of use thereof
07/12/2012US20120177647 Mdl-1 uses
07/12/2012US20120177646 Fgf21 mutants and uses thereof
07/12/2012US20120177645 Methods and compositions for the inhibition of transplant rejection
07/12/2012US20120177644 Mesenchymal stem cell differentiation
07/12/2012US20120177643 Human cdr-grafted antibody and antibody fragment thereof
07/12/2012US20120177642 Methods of treating inflammatory and autoimmune diseases with natalizumab
07/12/2012US20120177641 Gefitnib Sensitivity-Related Gene Expression and Products and Methods Related Thereto
07/12/2012US20120177640 Optimizing the production of antibodies
07/12/2012US20120177639 Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
07/12/2012US20120177638 Antibodies to vla-1
07/12/2012US20120177637 Method for selecting a single cell expressing a heterogeneous combination of antibodies
07/12/2012US20120177636 Carbohydrate-containing pan cancer marker
07/12/2012US20120177635 Methods of using apoptotic anti-ige antibodies
07/12/2012US20120177634 Demethylpenclomedine analogs and their use as anti-cancer agents
07/12/2012US20120177633 Methods for accelerating the healing of connective tissue injuries and disorders
1 ... 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 ... 1823